妊娠期特殊人群抗感染药物给药:药代动力学证据综述
妊娠期解剖和生理变化影响药物吸收、分布、代谢和排泄,可能降低母体抗感染药物浓度并影响疗效。本文系统检索PubMed,汇总并评价妊娠期抗感染药物(HIV、结核、疟疾和常见细菌感染)的药代动力学研究,发现已发表数据匮乏;仅考比司他增强抗逆转录病毒方案有明确结论不宜用于妊娠期,多数研究认为需进一步研究或存在临床意义不确定的药代动力学差异。
要点
- 妊娠期抗感染药物药代动力学数据匮乏,需关注母体浓度降低对疗效的潜在影响。
- 考比司他增强抗逆转录病毒方案有明确证据不支持妊娠期使用。
- 多数研究结论为需进一步研究或药代动力学差异临床意义不确定。
核心结论
- 妊娠期抗感染药物已发表药代动力学数据匮乏,尽管其临床重要性明确。
- 仅考比司他增强抗逆转录病毒方案有明确结论不宜用于妊娠期。
- 多数研究认为需进一步研究或存在临床意义不确定的药代动力学差异。
研究设计与样本
- 系统检索PubMed,纳入比较妊娠女性与非妊娠对照药代动力学或评估浓度与已知最低抑菌浓度关系的研究。
- 由两名独立评审员提取数据并使用24项ClinPK清单评价。
- 综述聚焦HIV、结核、疟疾和常见细菌感染治疗药物。
主要发现
- 妊娠期抗感染药物已发表数据匮乏。
- 考比司他增强抗逆转录病毒方案有明确结论不宜用于妊娠期。
- 多数研究结论为需进一步研究或药代动力学差异临床意义不确定。
- 现有质量评分体系应用于此类研究存在挑战。
临床怎么用
- 临床用药应关注妊娠期抗感染药物浓度可能降低对母体、胎儿和新生儿疗效的影响。
- 考比司他增强抗逆转录病毒方案不应在妊娠期使用。
- 对多数抗感染药物,妊娠期 dosing 需结合有限证据个体化评估。
局限性
- 妊娠特异性数据匮乏。
- 现有研究多未给出明确临床结论。
- 质量评价体系应用于特殊人群药代动力学研究存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substantial anatomical and physiological changes occur during pregnancy and labor, which impact on drug absorption, distribution, metabolism, and elimination. Reduced maternal concentrations may have a clinically important impact on the efficacy of anti-infectives for mother, fetus, and neonate, with potential dosing implications. However, there is a paucity of pregnancy-specific data examining this. Existing data on the pharmacokinetics of anti-infectives in pregnancy are summarized and evaluated, with emphasis on agents that are used in treatment of HIV, tuberculosis, malaria, and common bacterial infections. Limitations and challenges in achieving ideal study designs in pregnant populations are highlighted, and key quality considerations for the generation of the highest quality evidence are outlined. PubMed was searched for each chosen anti-infective. Pharmacokinetic studies which either compared pharmacokinetics from pregnant women against nonpregnant controls, or which assessed concentrations against a known minimum inhibitory concentration were included. Two independent reviewers extracted data from each study and appraised them using the 24-point ClinPK Checklist. The main finding was that there is a lack of published data for anti-infectives in pregnancy, despite their clinical importance. Of the studies identified, only those investigating cobicistat-boosted antiretroviral regimens firmly concluded that these should not be used in pregnancy. Most studies concluded either that further research was needed, or that there were significant pharmacokinetic differences between pregnant and nonpregnant participants which had uncertain clinical significance. Challenges in applying existing quality grading systems to these studies were noted, suggesting a development of a refined system for appraisal of pharmacokinetic studies in "special populations" may be warranted.
引用
- Hazenberg P, Navaratnam K, Busuulwa P, et al. Anti-Infective Dosing in Special Populations: Pregnancy. Clin Pharmacol Ther. 2021. PMID: 33548055. doi:10.1002/cpt.2192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。